Warfarin pharmacodynamics unaffected by cilomilast

Annals of Pharmacotherapy

Volumn 35, Issue 12, 2001, Pages 1535-1539

  Kelly, John ^a   Murdoch, Robert D ^a   Clark, David J ^a   Webber, Dawn M ^a   Fuder, Hermann ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

Cilomilast; Pharmacodynamics; Warfarin

Indexed keywords

CILOMILAST; PHOSPHODIESTERASE IV INHIBITOR; WARFARIN;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINUS ARRHYTHMIA; VERTIGO;

ADULT; ANTICOAGULANTS; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NITRILES; PHOSPHODIESTERASE INHIBITORS; WARFARIN;

EID: 0035666594     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10369     Document Type: Article

References (8)

1. Ariflo (SB-207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
2. Assessment and treatment of obstructive airways disease in the elderly
3. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease
4. Human liver microsomal metabolism of the enantiomers of warfarin and adenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
5. Clinically significant drug interactions
6. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers
7. Drug interactions with warfarin
8. What is the true clinical significance of plasma protein binding displacement interactions?